These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Oxygen removal during pathogen inactivation with riboflavin and UV light preserves protein function in plasma for transfusion. Feys HB; Van Aelst B; Devreese K; Devloo R; Coene J; Vandekerckhove P; Compernolle V Vox Sang; 2014 May; 106(4):307-15. PubMed ID: 24460692 [TBL] [Abstract][Full Text] [Related]
10. Highlights of PBTI Coimbra Conference on PRT of Plasma & Current Opinions on Pathogen Reduction Treatment of Blood Components. de Sousa G; Seghatchian J Transfus Apher Sci; 2015 Apr; 52(2):228-32. PubMed ID: 25770045 [TBL] [Abstract][Full Text] [Related]
11. Multilayer-strategy to enhance optimal safety of the blood supply: The role of pathogen inactivation for optimizing recipient safety and helping health care cost containment: Moderator views. Seghatchian J Transfus Apher Sci; 2015 Apr; 52(2):233-6. PubMed ID: 25748230 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of the effectiveness of a pathogen inactivation technology against clinically relevant transfusion-transmitted bacterial strains. Schmidt M; Hourfar MK; Sireis W; Pfeiffer U; Göttig S; Kempf VA; McDonald CP; Seifried E Transfusion; 2015 Sep; 55(9):2104-12. PubMed ID: 26013691 [TBL] [Abstract][Full Text] [Related]
15. The effect of pathogen reduction technology (Mirasol) on platelet quality when treated in additive solution with low plasma carryover. Johnson L; Winter KM; Reid S; Hartkopf-Theis T; Marschner S; Goodrich RP; Marks DC Vox Sang; 2011 Oct; 101(3):208-14. PubMed ID: 21492184 [TBL] [Abstract][Full Text] [Related]
16. Effect of Mirasol pathogen reduction technology system on in vitro quality of MCS+ apheresis platelets. Mastroianni MA; Llohn AH; Akkök ÇA; Skogheim R; Ødegaard ER; Nybruket MJ; Flesland A; Mousavi SA Transfus Apher Sci; 2013 Oct; 49(2):285-90. PubMed ID: 23820429 [TBL] [Abstract][Full Text] [Related]
17. Update on the use of pathogen-reduced human plasma and platelet concentrates. Seltsam A; Müller TH Br J Haematol; 2013 Aug; 162(4):442-54. PubMed ID: 23710899 [TBL] [Abstract][Full Text] [Related]
18. Robust inactivation of Plasmodium falciparum in red blood cell concentrates using amustaline and glutathione pathogen reduction. Sow C; Bouissou A; Girard YA; Singh GB; Bounaadja L; Payrat JM; Haas D; Isola H; Lanteri MC; Bringmann P; Grellier P Transfusion; 2022 May; 62(5):1073-1083. PubMed ID: 35385146 [TBL] [Abstract][Full Text] [Related]
19. Research opportunities for pathogen reduction/inactivation of blood components: summary of an NHLBI workshop. Klein HG; Glynn SA; Ness PM; Blajchman MA; Transfusion; 2009 Jun; 49(6):1262-8. PubMed ID: 19392769 [TBL] [Abstract][Full Text] [Related]
20. Design and development of a method for the reduction of infectious pathogen load and inactivation of white blood cells in whole blood products. Goodrich RP; Doane S; Reddy HL Biologicals; 2010 Jan; 38(1):20-30. PubMed ID: 20093041 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]